DENTSPLY SIRONA director receives RSU grant
HOSEIN CLYDE reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
HOSEIN CLYDE reported acquisition or exercise transactions in this Form 4 filing.
DENTSPLY SIRONA Inc. director Clyde Hosein received an equity award of 22,822 shares on June 3, 2026 at no cash cost per share. A footnote explains this grant consists entirely of restricted stock units that vest in full one year from the grant date.
After this compensation-related award, Hosein holds a total of 64,075.456 common shares directly. Because this is a stock grant rather than an open-market purchase, it reflects routine director compensation rather than a discretionary share purchase.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 22,822 | $0.00 | $0.00 |
Footnotes (1)
- F1. This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.
Key Figures
Key Terms
Restricted Stock Units (RSUs) financial
transaction code "A" regulatory
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did DENTSPLY SIRONA (XRAY) director Clyde Hosein report on this Form 4?
Was Clyde Hosein’s DENTSPLY SIRONA (XRAY) transaction an open-market purchase or a grant?
What are the vesting terms of Clyde Hosein’s RSU grant at DENTSPLY SIRONA (XRAY)?
Does this DENTSPLY SIRONA (XRAY) Form 4 show any stock sales by Clyde Hosein?
AI-generated analysis. How Rhea-AI works. Not financial advice.